[CNAT] Conatus Pharmaceuticals Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For CNAT
CNAT is in the long-term down -98% below S&P in 8 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -71.33% | ROE | -82.04% | ROI | ||
| Current Ratio | 10.09 | Quick Ratio | Long Term Debt/Equity | 0.04 | Debt Ratio | 0.11 | |
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | -30 K | Cash From Investing Activities | 4.37 M | Cash From Operating Activities | -5.95 M | Gross Profit | |
| Net Profit | -5.98 M | Operating Profit | -5.96 M | Total Assets | 32.32 M | Total Current Assets | 31.54 M |
| Total Current Liabilities | 3.13 M | Total Debt | 1000 K | Total Liabilities | 4.22 M | Total Revenue |
Technical Data
| High 52 week | 7.5 | Low 52 week | 0.71 | Last close | 0.86 | Last change | -3.21% |
| RSI | 54.13 | Average true range | 0.08 | Beta | 2.1 | Volume | 6.13 M |
| Simple moving average 20 days | 0.59% | Simple moving average 50 days | -35.2% | Simple moving average 200 days | -73.27% |
Performance Data
| Performance Week | -1.49% | Performance Month | 21.09% | Performance Quart | -57.84% | Performance Half | -82.77% |
| Performance Year | -83.24% | Performance Year-to-date | -78.23% | Volatility daily | 5.84% | Volatility weekly | 13.05% |
| Volatility monthly | 26.74% | Volatility yearly | 92.64% | Relative Volume | 56874.5% | Average Volume | 1.08 M |
| New High | New Low |
News
2019-08-19 09:00:01 | Conatus CNAT Upgraded to Strong Buy: Here's What You Should Know
2019-08-07 11:00:03 | Conatus CNAT Beats on Q2 Earnings, Stops Emricasan Studies
2019-08-06 19:25:11 | Conatus Pharmaceuticals CNAT Reports Q2 Loss, Tops Revenue Estimates
2019-08-06 16:05:00 | Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates
2019-07-31 10:36:02 | Will Conatus Pharmaceuticals CNAT Report Negative Q2 Earnings? What You Should Know
2019-07-25 13:46:33 | Investors Who Bought Conatus Pharmaceuticals NASDAQ:CNAT Shares Five Years Ago Are Now Down 96%
2019-06-26 16:17:31 | Conatus CNAT Stock Price Could Hit Zero
2019-06-26 08:37:12 | Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
2019-06-26 07:19:56 | The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
2019-06-26 06:07:10 | Conatus' Emricasan Lags Primary Goal in Liver Function Study
2019-06-25 11:32:45 | NASH Disappointment Forces Conatus To Explore Strategic Alternatives
2019-06-24 17:00:34 | UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial
2019-06-24 16:19:19 | Conatus Pharma to explore options, liver disease drug fails trial
2019-06-24 16:06:00 | Conatus to Explore Strategic Alternatives and Implement Restructuring Plan
2019-06-24 16:05:00 | Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
2019-06-12 18:27:10 | CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
2019-06-01 09:31:01 | Conatus CNAT Down 5.8% Since Last Earnings Report: Can It Rebound?
2019-05-28 11:48:03 | Conatus Down More Than 60% in the Past 90 Days: Here's Why
2019-05-24 09:39:55 | How Many Conatus Pharmaceuticals Inc. NASDAQ:CNAT Shares Do Institutions Own?
2019-05-06 14:53:06 | Conatus' CNAT Earnings, Revenues Miss Estimates in Q1
2019-05-02 19:15:11 | Conatus Pharmaceuticals CNAT Reports Q1 Loss, Lags Revenue Estimates
2019-05-02 18:11:35 | Conatus: 1Q Earnings Snapshot
2019-04-30 07:30:00 | Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis
2019-04-24 10:33:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2019-04-15 07:30:00 | Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
2019-04-07 09:30:01 | Why Is Conatus CNAT Down 37.8% Since Last Earnings Report?
2019-04-02 07:30:00 | Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
2019-03-22 17:43:09 | Conatus CNAT Declines on Failure of NASH Fibrosis Study
2019-03-22 10:49:15 | Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
2019-03-21 16:05:00 | Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
2019-03-20 11:10:03 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan
2019-03-13 10:35:02 | Implied Volatility Surging for Conatus CNAT Stock Options
2019-03-13 09:00:00 | Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
2019-03-11 10:57:02 | Conatus' CNAT Q4 Earnings Top Estimates, Emricasan in Focus
2019-03-08 20:24:59 | Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
2019-03-08 16:05:00 | Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
2019-03-01 07:30:00 | Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
2019-02-25 13:20:41 | Is Conatus Pharmaceuticals Inc.’s NASDAQ:CNAT CEO Pay Justified?
2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study
2019-02-12 07:30:00 | Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
2019-01-30 08:05:00 | Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
2019-01-29 10:05:03 | Can GW Pharmaceuticals GWPH Deliver a Beat in Q1 Earnings?
2019-01-28 07:30:00 | Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
2018-12-28 17:40:10 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan
2018-12-13 09:26:02 | The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
2018-12-12 10:03:03 | Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
2018-12-07 08:04:52 | The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
2018-12-06 14:51:07 | Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study